Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 10, 2003, Pages 824-826

  Gordon, Nancy ^a   Mullen, Craig A ^a   Tran, Hai ^a   Worth, Laura ^a   Almaguer, David Gomez ^b   Chan, Ka Wah ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

Bone marrow transplantation; Chediak Higashi syndrome; Fludarabine; Intravenous busulfan; Preparative regimen

Indexed keywords

BUSULFAN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; TACROLIMUS;

ALLOGENIC BONE MARROW TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CHEDIAK HIGASHI SYNDROME; CHIMERA; COMBINATION CHEMOTHERAPY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SIBLING;

BONE MARROW TRANSPLANTATION; BUSULFAN; CHEDIAK-HIGASHI SYNDROME; CHILD, PRESCHOOL; GRAFT VS HOST DISEASE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; SIBLINGS; TIME FACTORS; VIDARABINE;

EID: 0141889034     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200310000-00019     Document Type: Article

References (23)

1. Dinauer MC. The phagocyte system and disorders of granulopoiesis and granulocyte function. In: Nathan DG, Orkin SH, eds. Hematology of Infancy and Childhood. Philadelphia: WB Saunders; 1998:934-936.
2. Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metabol. 1999;68:283-303.
3. Boxer LA, Watanabe AM, Rister M, et al. Correction of leukocyte function in Chediak-Higashi syndrome by ascorbate. N Engl J Med. 1976;295:1041-1045.
4. Targan SR, Oseas R. The "lazy" NK cells of Chediak-Higashi syndrome. J Immunol. 1983;130:2671-2674.
5. Haddad E, Le Deist F, Blanche S, et al. Treatment of Chediak-Higashi syndrome by allogeneic bone marrow transplantation: report of 10 cases. Blood. 1995;85:3328-3333.
6. Mottonen M, Lanning M, Saarinen UM. Allogeneic bone marrow transplantation in Chediak-Higashi syndrome. Pediatri Hematol Oncol. 1995;12:55-59.
7. Trigg ME, Schugar R. Chediak-Higashi syndrome: hematopoietic chimerism corrects genetic defect. Bone Marrow 2001;27:1211-1213.
8. Virelizier JL, Lagrue A, Durandy A, et al. Reversal of natural killer defect in a patient with Chediak-Higashi syndrome after bone marrow transplantation. N Engl J Med. 1982;306:1055-1056.
9. Russell JA, Tran H, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8:468-476.
10. Leiper AD. Non-endocrine late complications of bone marrow transplantation in childhood. Br J Haematol. 2002;118:23-43.
11. Brennan BMD, Shalet SM. Endocrine late effects after bone marrow transplantation. Br J Haematol. 2002;118:58-66.
12. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002;8:145-154.
13. Day SD, McGuirk JP, Picken S, et al. Once-daily intravenous busulfan and cyclophosphamide followed by stem cell transplant for hematologic malignancies: dose modification protocol. Biol Blood Marrow Transplant. 2002;8:100 (abstr. 137).
14. deLima M, Shahjahan M, Madden T, et al. Fludarabine and IV Busulfan + ATG: low toxicity conditioning regimen for stem cell transplantation in AML and MDS: Preliminary results. Blood. 2002;98:345b (abstr. 5147).
15. Fernandez F, Tran HT, Albrecht F, et al. Evaluation of safety and pharmacokinetics of administrating intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant diseases undergoing stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:486-492.
16. Shaw PJ, Scharping CE, Brian RJ, et al. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood. 1994;84:2357-2362.
17. Shaughnessy PJ, Tran H, Andersson BS, et al. Pharmacokinetics of once daily dosing of intravenous busulfan in a reduced intensity preparative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:83 (abstr. 76).
18. Chan KW, Bekassy AN, Ha CS, et al. Fludarabine-based preparative protocol for unrelated donor cord blood transplantation in children: successful engraftment with minimal toxicity. Bone Marrow Transplant. 1999;23:849-851.
19. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
20. Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000;111:18-29.
21. Classen CF, Schulz AS, Sigl-Kraetzig M, et al. Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning. Bone Marrow Transplant. 2001;28:93-96.
22. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinetics. 2002;41:93-103.
23. Parkman R. Hematopoietic stem cell transplantation for primary immunodeficiency and metabolic diseases. Hematology 2000, American Society of Hematology Education Program Book, 2000:319-323.